PNS244 PAN-EU CLINICAL HTA – A NON-UNIFORM IMPACT?

CCE-appraised products had a significantly lower mean delay from EC-approval to national HTA publication in comparison to non-CCE markets (223 days and 324 days respectively; p=0.025) To date, drugs appraised under EUnetHTA JAs have been assessed in a shorter time by CCE markets in comparison to those appraised by non-CCE markets with a similar rate of positive appraisal. This may reflect a greater alignment between the JA clinical framework to CCE market HTA decision-drivers than the non-CCE markets or, may rather reflect natural assessment timelines of the HTA bodies involved. [Extracted from the article]